![Alliance News](https://static.lse.co.uk/images/news-logos/alliance-news-logo.png)
TRADING UPDATES: MaxCyte strikes deal; Barkby sells Workshop
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
Read moreFri, 21st Feb 2020 11:53
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
Read more(Alliance News) - MaxCyte Inc on Monday said it signed a strategic platform licence with Vittoria Biotherapeutics to advance cellular therapies.
Read more(Sharecast News) - MaxCyte announced a strategic platform licence agreement with Vittoria Biotherapeutics on Monday, granting Vittoria non-exclusive clinical and commercial rights to use MaxCyte's 'Flow Electroporation' technology and 'ExPERT' platform.
Read more(Sharecast News) - Cell engineering platform technology company MaxCyte announced a strategic platform licence (SPL) agreement with Lyell Immunopharma - a clinical-stage T-cell reprogramming company - on Thursday.
Read more(Alliance News) - MaxCyte Inc on Thursday said it has signed a strategic platform license with Lyell Immunopharma Inc, a clinical stage T cell reprogramming company.
Read more(Sharecast News) - Cell engineering specialist MaxCyte saw its shares slide on Thursday, after it updated its revenue guidance for the year on the back of its first quarter performance.
Read more(Alliance News) - MaxCyte Inc on Thursday reported a widened operating loss in the first quarter of 2023 as revenue fell and costs were higher.
Read moreMaxCyte Inc - cell-engineering technology platform based in US state of Maryland - Signs a strategic platform license with Walking Fish Therapeutics Inc, a biotechnology company that is "rapidly advancing B cell-based therapeutics." Under the terms of the agreement, Walking Fish obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform. In return, MaxCyte is entitled to receive platform licensing fees, clinical milestone payments and sales-based payments.
Read moreThursday 4 May | |
Apax Global Alpha Ltd | Q1 Results |
BAE Systems PLC | Trading Statement |
Cardiff Property PLC | Half Year Results |
Derwent London PLC | Trading Statement |
e-Therapeutics PLC | Full Year Results |
Glanbia PLC | Q1 Results |
IMI PLC | Trading Statement |
Mondi PLC | Trading Statement |
Morgan Sindall Group PLC | Trading Statement |
Next PLC | Trading Statement |
Rathbones Group PLC | Trading Statement |
Shell PLC | Q1 Results |
Spirent Communications PLC | Trading Statement |
Trainline PLC | Full Year Results |
Virgin Wines UK PLC | Half Year Results |
Wheaton Precious Metals | Q1 Results |
Friday 5 May | |
Eqtec PLC | Full Year Results |
InterContinental Hotels Group PLC | Trading Statement |
International Consolidated Airlines Group SA | Q1 Results |
Monday 8 May | |
no events scheduled | |
Tuesday 9 May | |
Kosmos Energy Ltd | Q1 Results |
Tialis Essential IT PLC | Full Year Results |
Treatt PLC | Half Year Results |
Wednesday 10 May | |
Anexo Group PLC | Full Year Results |
Asos PLC | Half Year Results |
Compass Group PLC | Half Year Results |
Directa Plus PLC | Full Year Results |
Georgia Capital PLC | Q1 Results |
MaxCyte Inc | Q1 Results |
Spirax-Sarco Engineering PLC | Trading Statement |
Valeura Energy Inc | Q1 Results |
Vertu Motors PLC | Full Year Results |
Copyright 2023 Alliance News Ltd. All Rights Reserved. |
MaxCyte Inc - cell-engineering technology platform based in US state of Maryland - Non-Executive Chair Richard Douglas buys 80,000 shares at average USD4.32, worth USD345,480, on Wednesday. Now has 100,000 shares, a 0.1% stake.
Read more(Sharecast News) - Cell engineering technology company MaxCyte announced the appointment of Douglas Swirsky as its new chief financial officer on Tuesday.
Read more(Alliance News) - MaxCyte Inc on Tuesday said it appointed Douglas Swirsky as its new chief financial officer, effective immediately.
Read more(Sharecast News) - Cell engineering specialist MaxCyte reported total revenue of $12.4m in the fourth quarter of 2022 on Thursday, making for an increase of 22% year-on-year.
Read more(Alliance News) - MaxCyte Inc on Thursday said revenue was up by a third in 2022, as it expects further growth in 2023.
Read moreMaxCyte Inc - Maryland, US-based cell-engineering focused company - Forms new scientific advisory board that will reflect on research in molecular design and cell engineering and gain an understanding of translational development, in order to leverage the benefits of impactful discoveries for therapeutic applications. Board will include scientists, Oliver Rando, Marcela Maus, Avery Posey and Nako Nakatsuka.
Read more